GlassScriptPhysician profile
Robert S Cleveland
NPI 1942274998
$2,172.09
in general payments reported to CMS, 2019-2025
25 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $128 · 2021: $180 · 2022: $235 · 2023: $413 · 2024: $329 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $972.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $557.89 | 2019-2023 | Liletta, Lo Loestrin Fe |
| Astellas Pharma US INC | $438.50 | 2023-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $311.99 | 2019-2025 | Novasure, Myosure Tissue Removal Device, Acessa Provu System |
| Idorsia Pharmaceuticals US INC | $116.10 | 2023 | Quviviq |
| Pfizer INC. | $102.86 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $75.61 | 2023-2024 | Myfembree |
| Roche Diagnostics Corporation | $72.21 | 2019 | |
| Therapeuticsmd, INC. | $66.77 | 2019-2022 | |
| Ethicon US, LLC | $64.14 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.05 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $47.10 | 2022-2023 | |
| Avion Pharmaceuticals | $38.46 | 2019 | |
| Lupin INC. | $30.87 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.76 | 2019 | |
| Scynexis, INC. | $20.95 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $19.64 | 2020 | |
| Coopersurgical, INC. | $18.09 | 2019 | |
| Organon LLC | $17.37 | 2025 | Nexplanon |
| Duchesnay USA Incorporated | $15.60 | 2019 | |
| Evofem Biosciences, INC. | $15.11 | 2021 | |
| Baxter Healthcare | $13.54 | 2022 | |
| Agile Therapeutics, INC. | $13.31 | 2024 | Twirla |
| Myovant Sciences INC. | $13.01 | 2021 | |
| Amgen INC. | $11.81 | 2021 | |
| Olympus America INC. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cleveland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.